8-K: Immunocore Reports Strong Q2 Revenue Growth Driven by KIMMTRAK Sales and Provides Clinical Trial Updates

Immunocore announced a 32% increase in KIMMTRAK sales for Q2 2024, alongside updates on multiple clinical trials and pipeline advancements.

Summary

• Immunocore reported a net product revenue of $75.3 million for the second quarter of 2024, a 32% increase compared to the same period in 2023.
• The company's lead product, KIMMTRAK, generated $75 million in net sales for the quarter and $146 million for the first six months of 2024, representing a 32% and 34% increase year-over-year, respectively.
• US sales of KIMMTRAK were $55.6 million for the quarter, with $15.4 million from Europe and $4.3 million from international regions.
• The company is progressing three Phase 3 trials with registrational data expected in 2026, 2027, and 2028.
• Research and development expenses increased to $51.1 million for the quarter, driven by the PRAME programs and the initiation of a Phase 3 clinical trial.
• The company's net loss for the quarter was $11.6 million, an improvement from the $17.0 million loss in the same period of 2023.
• Cash, cash equivalents, and marketable securities totaled $859.6 million as of June 30, 2024.
• Immunocore plans to repay $50 million of its existing loan by the end of 2024 and expects to pay approximately $40 million in sales-related rebate accruals in the second half of 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, clinical trial advancements, and a robust cash position. The delay in the HIV data release is a minor setback, but the overall tone is optimistic.

Positives

• KIMMTRAK sales are growing significantly, driven by increased penetration in the US and global expansion.
• The conversion of the TEBE-AM trial to a Phase 3 trial is expected to accelerate the time to final endpoint.
• The company has a strong cash position of $859.6 million.
• The company is advancing multiple clinical programs across oncology, infectious diseases, and autoimmune diseases.
• The company is seeing positive clinical data for brenetafusp in multiple tumor types.
• The company is expanding its pipeline with new candidates for autoimmune diseases.

Negatives

• The company experienced a net loss of $11.6 million for the quarter.
• The company is facing a challenging market access environment in Europe.
• The planned data release for the HIV MAD trial has been moved from Q4 2024 to Q1 2025.
• The company expects to pay approximately $40 million in sales-related rebate accruals in the second half of 2024.

Risks

• The company faces risks related to the commercial performance of KIMMTRAK and its expansion into new indications.
• There are risks associated with the design, progress, timing, and results of the company's clinical trials.
• The company's ability to obtain regulatory approval for its product candidates is not guaranteed.
• The company faces competition in the market for its product candidates.
• The company's need for and ability to obtain additional funding is subject to market conditions.
• The company is exposed to risks related to intellectual property protection and the success of collaborations.

Future Outlook

Immunocore expects to present multiple data read-outs over the next 18 months, including brenetafusp and HIV MAD data, while progressing three Phase 3 trials with registrational data expected in 2026, 2027, and 2028. The company also plans to advance new autoimmune and oncology clinical and pre-clinical programs.

Management Comments

• Over the next 18 months, we will present multiple data read-outs including brenetafusp and the HIV MAD data, while progressing three Phase 3 trials, with registrational data expected in 2026, 2027 and 2028, said Bahija Jallal, Chief Executive Officer of Immunocore.
• We will also advance our new autoimmune and oncology clinical and pre-clinical programs, said Bahija Jallal, Chief Executive Officer of Immunocore.
• In the first half of 2024, we expanded KIMMTRAKs reach in the US community setting and globally with 9 new launches and 2 additional reimbursement agreements, in the context of a challenging market access environment in Europe, said Ralph Torbay, Immunocores Chief Commercial Officer.
• We are exploring the potential of KIMMTRAK to benefit more patients and deliver revenue growth beyond metastatic uveal melanoma with our two ongoing Phase 3 registrational trials in previously treated cutaneous melanoma and in adjuvant uveal melanoma.

Industry Context

This announcement highlights Immunocore's progress in the competitive biotechnology landscape, particularly in the development of novel immunotherapies for cancer, infectious diseases, and autoimmune conditions. The company's focus on T-cell receptor (TCR) technology and bispecific antibodies positions it as a key player in the next generation of immunomodulating medicines. The expansion of KIMMTRAK's market reach and the advancement of multiple clinical trials demonstrate the company's commitment to addressing unmet medical needs.

Comparison to Industry Standards

• Immunocore's 32% year-over-year growth in KIMMTRAK sales is strong compared to other commercial-stage biotech companies, such as Xencor, which reported a 20% increase in revenue for Q1 2024.
• The company's focus on bispecific T-cell engagers, like brenetafusp, aligns with the industry trend towards more targeted and effective immunotherapies, similar to Amgen's Blincyto and Regeneron's Libtayo.
• The conversion of the TEBE-AM trial to a Phase 3 trial is a positive development, as it could accelerate the time to market for KIMMTRAK in cutaneous melanoma, a market where companies like Bristol Myers Squibb with Opdivo and Merck with Keytruda are dominant.
• The company's expansion into autoimmune diseases with its ImmTAAI platform is a strategic move, as this area is attracting significant investment and innovation, with companies like AbbVie and Johnson & Johnson leading the way.
• The company's cash position of $859.6 million is robust, providing a strong financial foundation for its ongoing clinical trials and commercialization efforts, which is comparable to other biotech companies at a similar stage of development, such as Arcus Biosciences.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and clinical trial progress.
• Employees may be encouraged by the company's positive performance and future prospects.
• Patients may benefit from the development of new therapies for cancer, infectious diseases, and autoimmune conditions.
• Customers will have access to KIMMTRAK in more countries.
• Suppliers will benefit from the company's increased commercial activity.
• Creditors will be reassured by the company's strong financial position.

Next Steps

• The company will continue to enroll patients in ongoing clinical trials.
• The company plans to present clinical data for brenetafusp in late-line non-small cell lung cancer (NSCLC) in the fourth quarter of 2024.
• The company will continue to advance its new autoimmune and oncology clinical and pre-clinical programs.
• The company will present multiple data read-outs over the next 18 months.
• The company will repay $50 million of its existing loan by the end of 2024.
• The company will pay approximately $40 million in sales-related rebate accruals in the second half of 2024.

Key Dates

Keywords

KIMMTRAK, Immunocore, brenetafusp, cutaneous melanoma, uveal melanoma, clinical trials, ImmTAC, ImmTAV, ImmTAAI, oncology, autoimmune, infectious diseases, PRAME, T cell therapy